A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects

A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects

Feng Yao,1,* Chenguang Wang,2,* Jie Ding,1 Qian Zhang,1 Liang Zheng,1 Qin Zhang,1 Tianshu Yang,2 Xunmin Zhang,2 Yong Shan,2 Sheng Hou,2 Hao Wang,2 Renpeng Zhou,1 Wei Hu1 1Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, People’s...

Full description

Bibliographic Details
Main Authors: Yao F, Wang C, Ding J, Zhang Q, Zheng L, Yang T, Zhang X, Shan Y, Hou S, Wang H, Zhou R, Hu W
Format: Article
Language:English
Published: Dove Medical Press 2024-08-01
Series:Drug Design, Development and Therapy
Subjects:
cmab015
secukinumab
biosimilar
pharmacokinetics
safety
immunogenicity
Online Access:https://www.dovepress.com/a-randomized-double-blind-parallel-group-phase-i-study-comparing-the-p-peer-reviewed-fulltext-article-DDDT

Internet

https://www.dovepress.com/a-randomized-double-blind-parallel-group-phase-i-study-comparing-the-p-peer-reviewed-fulltext-article-DDDT

Similar Items